Baird analyst Jack Allen initiated coverage of Crispr Therapeutics with a Neutral rating and $46 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $102 from $110 at Oppenheimer
- Crispr Therapeutics reports Q4 EPS ($1.41) vs. ($1.84) y/y
- Crispr Therapeutics price target lowered to $82 from $122 at Needham
- Crispr Therapeutics price target lowered to $123 from $153 at Chardan
- Crispr Therapeutics price target lowered to $65 from $78 at Credit Suisse